Machine learning predicts drug cardiotoxicity

Machine learning is playing a key role in predicting all major forms of drug cardiotoxicity, potentially helping reduce late-stage clinical trial failures.

Namely, researchers from the Computational Cardiovascular Science Group of the University of Oxford and Insilico Medicine showed how their “machine learning algorithm can identify drugs that can cause six potential forms of cardiac adverse outcomes from gene expression data,” according to one study author Blanca Rodriguez, from the department of computer science at University of Oxford. The researchers published their findings in Frontiers in Pharmacology.

The study demonstrated the algorithm’s prediction on a curated dataset of transcriptional and molecular profiles, including 1,131 drugs, 35% with known cardiotoxicities, and 9,933 samples. The six forms of drug cardiotoxicity included: cardiac disorders signs and symptoms, cardiac arrhythmias, heart failure, coronary artery disease, pericardial disorders, and myocardium disorders.

Researchers collected the data and then proposed and implemented a chain of classifiers “with nested stacking approach” to classify drugs based on their risk to predict forms of cardiotoxicity. Across all cardiotoxicity types on a leave-drug-out cross-validation strategy, the machine learning method achieves a 0.80 average AUC on 291 drugs.

The leave-drug-out cross-validation strategy models could discriminate between safe and unsafe drugs with a 0.70 AUC across cardiotoxicity types, but the model was more accurate for some specific drug effects and types of agents, including “pericardial disease, cardiac disease and symptoms, heart failure and myocardial disease for antineoplastic, anti-inflammatory, cardiovascular and central nervous system agents, respectively,” researchers wrote.

The model could predict both acute and chronic effects of drugs.

“Using transcriptional and molecular features, all investigated forms of drug-induced cardiotoxicity were predicted with relatively good accuracy using the proposed chain of classifiers model with nested stacking trained with leave-drug-out cross-validation, and for all algorithms considered…” researchers wrote.

 

Related Cancer Therapy Cardiotoxicity Content:

Succeeding with Cancer: Using Imaging to Avoid Treatment-induced Heart Failure

Providers must rethink traditional imaging approaches to prevent cardiotoxicity in cancer patients

CV programs struggling to keep up with growing demand for cardio-oncologists

Prior cardiotoxicity linked to 30% increased risk of CHF during pregnancy

CV outcomes underreported in pivotal anticancer trials

CDK2 inhibitors protect cancer patients from anthracycline-induced cardiotoxicity

Genetic variants could be key to identifying chemo-induced cardiotoxicity

T2 mapping may uncover cardiotoxic marker early enough to prevent heart failure

Some chemo drugs might be more heart-safe than others

Cardiac MRI-derived T2 mapping may help heart failure patients

Genetic variant linked to chemotherapy-induced cardiomyopathy

Study calls for better collaboration between cardiologists, oncologists

Cardiac monitoring may protect high-risk breast cancer patients against heart failure

ASE: Biomarkers may predict chemo-related cardiotoxicity

Find more cardiac ultrasound news and video

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The scheme took place over a period of at least seven years, resulting in Medicare being billed for more than $70 million in fraudulent claims for unnecessary scans. 

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals.